Nutrition Therapy Extends Pancreatic Cancer Survival by 34% in Landmark Trial

DENVER, CO – March 12, 2026 – In a development that offers a rare glimmer of hope for one of the world's deadliest cancers, a new clinical trial has shown that a medically supervised nutrition therapy can significantly extend the lives of patients with stage IV pancreatic cancer. The study, led by metabolic health company Virta Health in partnership with top cancer centers, found that adding the specialized diet to standard chemotherapy extended patient survival by 34%.

The results, published in the peer-reviewed journal Cancer, represent a potentially seismic shift in a field where progress has been painfully slow. For patients with metastatic pancreatic cancer, where the median life expectancy is often less than a year, the findings suggest that what a patient eats could become a powerful new weapon in their therapeutic arsenal.

A New Hope for a Deadly Disease

Pancreatic cancer carries a notoriously grim prognosis. According to the American Cancer Society, the five-year survival rate for patients whose cancer has metastasized to distant parts of the body is a stark 3%. Most patients are diagnosed at this late stage, as the disease rarely causes symptoms until it has already spread, leaving chemotherapy as the primary, though often limited, treatment option.

Against this bleak backdrop, the results from Virta's Phase II randomized controlled trial are extraordinary. The study enrolled patients with stage IV metastatic pancreatic cancer, all of whom received a standard triplet chemotherapy regimen of gemcitabine, nab-paclitaxel, and cisplatin. Patients were then randomized into two groups: one receiving the standard diet and the other receiving Virta's individualized nutrition therapy.

The outcomes were significant. Patients in the Virta group lived an average of 13.7 months, compared to 10.2 months for those in the control group—a 3.5-month or 34% improvement in overall survival. Furthermore, progression-free survival—the length of time during and after treatment that the disease does not worsen—improved by 37%, from 6.2 months to 8.5 months. Critically, these gains were achieved without any added toxicity or decline in the patients' quality of life.

“Pancreatic cancer is among the deadliest cancers, and improving outcomes by any margin is rare,” said Dr. Adam Wolfberg, Chief Medical Officer of Virta Health, in a press statement. “Seeing a nutritional intervention—delivered remotely and safely—make this level of impact is extraordinary.”

The Science of Synergy: Nutrition Meets Chemotherapy

The intervention at the heart of the study is Virta's well-established nutrition therapy, a program that combines a well-formulated ketogenic diet with continuous remote medical supervision, one-on-one coaching, and AI-powered tools. While the company has built its reputation on reversing metabolic diseases like type 2 diabetes, this trial explores its application in oncology.

The scientific rationale is rooted in the unique metabolism of cancer cells. Many tumors, including pancreatic cancer, are voracious consumers of glucose, a phenomenon known as the "Warburg effect." By severely restricting carbohydrates, a ketogenic diet forces the body to produce and use ketones for energy instead of glucose. While healthy cells can readily adapt to using ketones, many cancer cells are metabolically inflexible and struggle to do so, potentially slowing their growth.

While the exact mechanism for the improved outcomes is still under investigation, researchers believe the nutritional approach may do more than just "starve" cancer cells. It may also alter the tumor microenvironment and enhance the effectiveness of chemotherapy.

“The mechanism of action is not fully understood, but this nutrition approach has shown in preclinical work to improve the effect of anti-cancer therapy, and that was shown in this clinical trial,” explained Dr. Erkut Borazanci, a lead author of the study paper and director of the Oncology Research Division of HonorHealth Research Institute. The full study is titled, A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer (Cancer, DOI: 10.1002/cncr.xxxx).

Beyond Metabolic Health: Virta's Leap into Oncology

The trial's success marks a major strategic milestone for Virta Health. The company, valued at $2 billion in its last funding round, has primarily focused on the massive market for metabolic diseases, partnering with employers and health plans to reverse type 2 diabetes and obesity in their populations. This foray into oncology validates its core thesis—that nutrition is a powerful tool for addressing the root causes of disease—and opens up a vast new therapeutic area.

“These results further validate that Virta’s approach isn’t about weight loss or calorie counting—it’s about addressing the root cause of metabolic dysfunction that drives disease,” Wolfberg noted. “That’s why our method works not only to reverse obesity and type 2 diabetes, but now shows promising synergistic effects alongside traditional cancer therapies.”

This expansion signals a maturation of the digital health industry, where technology-enabled lifestyle interventions are moving from wellness and chronic disease management into complex, high-stakes fields like oncology. For Virta, it is a deliberate move to prove the broad applicability of its platform.

“This is not a lucky signal,” said Virta CEO Sami Inkinen. “This study offers our first indication that the Virta platform may improve outcomes in even the deadliest conditions, and will guide us as we further build our pipeline of programs and research.”

The Path Forward: From Promising Signal to Standard Care

While the Phase II results are highly encouraging, the researchers are clear that more work is needed. The trial was designed to test for feasibility and a preliminary signal of efficacy. The next crucial step is a larger, more definitive Phase III trial to confirm these findings.

Dr. Borazanci and his colleagues have expressed their hope to launch such a study, which would be necessary before this nutritional therapy could be considered for inclusion in standard cancer care guidelines. If the results are replicated, it could pave the way for a new paradigm in which medically supervised nutritional interventions are prescribed alongside chemotherapy and radiation as a core component of cancer treatment.

For now, the study provides a powerful proof of concept and a much-needed dose of optimism for patients and clinicians who have long battled one of medicine's most formidable foes. It suggests that the future of cancer care may lie not only in developing new drugs, but also in harnessing the synergistic power of nutrition to make existing treatments work better.